{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:43Z","timestamp":1787010163563,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Concern for immune-related adverse events from immunotherapy and radiation therapy are well-documented; however, side effects are mostly mild to moderate. However, high-grade, potentially life-threatening adverse events are increasing. While case reports regarding immunotherapy-related bullous pemphigoid (BP) have been rising, only 1 has described BP following concomitant use of both nivolumab and radiation therapy (RT). For that patient, nivolumab was used for 10\u200aweeks prior to RT and development of PB followed 7 weeks later. This case presents a patient who tolerated nivolumab well for 38\u200amonths prior to developing BP less than 2 weeks after completing RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We present the case of DH, a 67-year-old gentleman on nivolumab for metastatic renal cell carcinoma to the lung since May of 2017. Following progressing lung nodules, the patient had his nivolumab paused and completed a course of short-beam radiation therapy. After restarting nivolumab post-radiation, the patient presented with itchy rash and blisters on his arm, legs, and trunk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>DH consulted dermatology following development of rash and was diagnosed with bullous dermatosis, likely bullous pemphigoid. Bullous pemphigoid following concomitant nivolumab (OPDIVO), despite prior tolerance and no history of autoimmune disease, was confirmed by biopsy a month later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Initial treatment was betamethasone 0.05% cream mixed 1:1 with powder to form paste applied twice daily. Given progressive symptoms and confirmatory biopsy of BP, nivolumab was held and 100\u200amg doxycycline and 80\u200amg prednisone daily was prescribed for a week, reduced to 60\u200amg during the second week.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>A week following discontinuation of nivolumab and beginning of doxycycline and prednisone, the blistering and rash was almost entirely resolved. Four months later, nivolumab was restarted and the patient continued low-dose tapering of prednisone until December. Since completing prednisone, the patient has shown no recurrence of bullous pemphigoid and has not developed any other immune-related adverse events to nivolumab upon rechallenge. Follow-up through October 2021 demonstrates the patient's sites of disease, both in- and out-field, have remained responsive to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Treating physicians should be aware of off-target effects of radiotherapy for oligoprogressive disease, which may include abscopal toxicities and the development of new immune-related adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000028199","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T08:05:08Z","timestamp":1639123508000},"page":"e28199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8655-8587","authenticated-orcid":false,"given":"Linda My","family":"Huynh","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center College of Medicine, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Bonebrake","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center College of Medicine, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"DiMaio","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Baine","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Teply","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R2-20250504","first-page":"e3860","article-title":"Abscopal effect, from myth to reality: from radiation oncologists\u2019 perspective","volume":"11","author":"Yilmaz","year":"2019","journal-title":"Cureus"},{"key":"R3-20250504","first-page":"40","article-title":"Nivolumab-induced severe bullous pemphigoid in a patient with renal cancer: a case report and literature review","volume":"6","author":"Wu","year":"2020","journal-title":"J Cancer Metastasis Treat"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000487127","article-title":"Intensity-modulated radiotherapy triggers onset of bullous pemphigoid in a patient with advanced melanoma treated with nivolumab","volume":"11","author":"Tanita","year":"2018","journal-title":"Case Rep Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PDL1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000362208","article-title":"Relationship between radiation therapy and bullous pemphigoid","volume":"229","author":"Nguyen","year":"2014","journal-title":"Dermatology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1089\/ars.2017.7267","article-title":"Targeted and off-target (bystander and abscopal) effects of radiation therapy: redox mechanisms and risk\/benefit analysis","volume":"29","author":"Pouget","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"R10-20250504","first-page":"01","article-title":"Radiation-induced inflammation and autoimmune diseases","volume":"5","author":"Yahyapour","year":"2018","journal-title":"Mil Med Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:08:08Z","timestamp":1746320888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028199"}},"subtitle":["A case report of abscopal toxicities"],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":10,"journal-issue":{"issue":"49","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028199","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"2021-07-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}